EZR and breast carcinoma: In our previous studies, it was established that NHERF1, an adaptor protein with two non-identical, type 1 tandem PDZ domains and a carboxyl-terminal ezrin-binding domain, is a potential candidate of clinical relevance for human breast cancer [16, 24, 50, 51].